CVS Caremark announced on May 28, 2026, that Eli Lilly's GLP-1 obesity medications Zepbound (tirzepatide) and oral Foundayo (orforglipron) will be added to its formulary. This reverses a previous exclusion and significantly expands patient access. The decision impacts commercial plans administered by CVS Caremark, including many Aetna and Cigna employer plans. Billing teams should prepare for an increase in prior authorization and medical necessity review requests for these agents. Monitor plan-specific bulletins for coverage criteria and step-therapy requirements. The move also pressures other PBMs to follow suit, potentially shifting the broader payer coverage landscape for weight management drugs in late 2026.